SCHEMBL3018826

SCHEMBL3018826

N#CCc1cccc(Nc2nc(Nc3ccc(OCCN4CCCC4)cc3)nc3[nH]ccc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.46
JAK3 P52333 6/20 0.46
BRD4 O60885 5/20 0.46
BRDT Q58F21 2/20 0.46
BRD2 P25440 1/20 0.46
BRD3 Q15059 1/20 0.46
SRC P12931 7/20 0.45
JAK1 P23458 3/20 0.45
HRH3 Q9Y5N1 2/20 0.45
PTK2 Q05397 2/20 0.45
RET P07949 2/20 0.45
TYK2 P29597 2/20 0.45
FLT3 P36888 2/20 0.45
ABL1 P00519 2/20 0.45
EGFR P00533 2/20 0.45
LCK P06239 2/20 0.45
FYN P06241 2/20 0.45
YES1 P07947 2/20 0.45
LYN P07948 2/20 0.45
PDGFRB P09619 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3030390 0.87 AXL (0.49) JAK2JAK3SRCHRH3PTK2
SCHEMBL3030244 0.84 IGF1R (0.44) JAK2JAK3BRD4PTK2EGFR
SCHEMBL13213035 0.82 PAK4 (0.48) JAK2JAK3BRD4JAK1PTK2
SCHEMBL3018200 0.81 AXL (0.61) JAK2JAK3BRD4JAK1PTK2
SCHEMBL3024528 0.80 JAK2 (0.65) JAK2JAK3BRD4JAK1PTK2
SCHEMBL3022389 0.79 JAK2 (0.53) JAK2JAK3BRD4PTK2RET
SCHEMBL3032288 0.78 AXL (0.50) LCKKDRAXLINSRBTK
SCHEMBL3026944 0.77 LRRK2 (0.57) JAK2JAK3BRD4PTK2PDGFRB
SCHEMBL3030399 0.77 JAK2 (0.51) JAK2JAK3BRD4PTK2EGFR
SCHEMBL13883682 0.76 AXL (0.50) JAK2JAK3SRCHRH3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393814-A1 PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS SuperGen, Inc. (US) 2011-12-14 EP disclosed
US-20100204221-A1 Pyrrolopyrimidinyl axl kinase inhibitors TOLERO PHARMACEUTICALS, INC. 2010-08-12 US disclosed
US-20100204221-A1 Pyrrolopyrimidinyl axl kinase inhibitors TOLERO PHARMACEUTICALS, INC. 2010-08-12 US disclosed
US-20100204221-A1 Pyrrolopyrimidinyl axl kinase inhibitors TOLERO PHARMACEUTICALS, INC. 2010-08-12 US disclosed
WO-2010090764-A1 PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS SUPERGEN, INC. (US) 2010-08-12 WO disclosed
WO-2010090764-A1 PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS SUPERGEN, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204221-A1 Pyrrolopyrimidinyl axl kinase inhibitors AXL, FLT3, TYRO3 JAK2 81/4885JAK3 131/4885BRD4 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.